QGEN Stock Analysis: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$41.44
-0.07 (-0.17%)
▼
5d:
+5.85%
30d:
+11.94%
90d:
+1.35%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
20d
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: QGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: QGEN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.89
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$34.70
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $41.44, which is considered extended relative to its 30-day fair value range of $36.73 to $39.96. The stock's valuation (Forward PE: 15.7) is in line with its historical norms (15.9). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, QGEN is in a strong downtrend. The price is approaching resistance at $38.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: QGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, QGEN is in a strong downtrend. The price is approaching resistance at $38.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: QGEN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$36.73 -
$39.96
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($44.46)
Trading Range Analysis
30-Day Trading Range
$36.73 -
$39.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$35.46
Resistance Level
$38.10
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.73
Wall Street Target
$44.46
(+7.3%)
Revenue Growth (YoY)
1.8%
Earnings Growth (YoY)
-23.8%
Profit Margin
19.2%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
15.7 vs 15.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$41.32
(0%)
2-Year Target
$41.19
(-1%)
3-Year Target
$41.07
(-1%)
3-Yr Target (if PE normalizes)
(PE: 16→16)
$41.51
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.9%)
$72.06
(+74%)
Base:
(SPY PE: 15.7, Growth: 7.9%)
$52.05
(+26%)
Bear:
(PE: 13.4, Growth: 7.9%)
$44.25
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 21.18 | Current EPS (TTM): $1.96
Bull Case
$61.37
(+48%)
Analyst growth 34.4%, PE expands to 23.3
Base Case
$55.79
(+35%)
Market implied 34.4%, PE stable at 21.2
Bear Case
$28.23
(-32%)
Severe decline -20.0%, PE contracts to 18.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.7 to 15.9
Stabilization Target:
$41.88
(+1.1%)
PE Expansion Potential:
+1.1%
Share & Embed Analysis
Last updated: July 13, 2026 7:25 PM ET
Data refreshes hourly during market hours. Next update: 8:25 PM
Data refreshes hourly during market hours. Next update: 8:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$591 | 64 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 67 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$157 | 60 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$271 | 54 HOLD |
